FDA Approves Genentech’s Rituxan For Rare Autoimmune Disease Pemphigus Vulgaris

Genentech, announced on 6/8/2018 that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes.